TeamDrive
RUS

RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide.

The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Leonid Melamed"It is strategically important that Russian developers of innovative pharmaceuticals appear large in number. Three or thirty companies of this kind in place will not resolve the problem. In the Silicon valley - there are tens of thousands of them, therefore the probability of success is rather high. Drug development industry is alive only if millions of people are dealing with it consolidated in tens of thousands of companies. To make this happen at our place, people with good ideas should be aware of how to become an accurate applicant, and also there must be institutions willing to invest and perform a function of business angels".

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more